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Abstract
Lymphangioleiomyomatosis (LAM) is a rare and progressive systemic disease affecting mainly young women of
childbearing age. A deterioration in lung function is driven by neoplastic growth of atypical smooth muscle-like LAM cells
in the pulmonary interstitial space that leads to cystic lung destruction and spontaneous pneumothoraces. Therapeutic
options for preventing disease progression are limited and often end with lung transplantation temporarily delaying an
inevitable decline. To identify new therapeutic strategies for this crippling orphan disease, we have performed array based
and metabolic molecular analysis on patient-derived cell lines. Our results point to the conclusion that mitochondrial
biogenesis and mitochondrial dysfunction in LAM cells provide a novel target for treatment.
Introduction
Ten-year survival of the progressive and systemic orphan
disease, Lymphangioleiomyomatosis (LAM) (1–9/
1,000,000 adult women) [1], ranges from 40% to 79% [2],
but these ﬁgures do not fully capture the signiﬁcant and
debilitating reduction in life-quality experienced by most
sufferers. While a number of organs can be affected,
including the kidney and associated lymph nodes, it is the
deterioration in lung function, which leads to disease pro-
gression. The early disease symptoms of LAM show high
similarity to asthma, chronic obstructive pulmonary disease,
and other obstructive lung diseases; therefore, the condition
is frequently misdiagnosed [3]. Only through a combination
of computer tomography, serological testing of increased
serum vascular endothelial growth factor-D (VEGFD), and
matrix metalloproteinase (MMP) levels, and lung biopsy,
can clinicians conﬁrm a LAM diagnosis with conﬁdence
[4]. Although the progression of the disease is relatively
slow, most patients suffer from accelerating respiratory
failure and can experience decades long dyspnea before
lung transplantation is considered as a “last-resort” therapy.
LAM is caused by inherited (TSC-LAM) or acquired
(sporadic or S-LAM) mutations of the tumor suppressor
tuberous sclerosis complex (TSC) genes TSC1 (hamartin)
or TSC2 (tuberin) [3]. The TSC1–TSC2 complex interacts
with various signaling pathways and is also involved in
regulation of the mechanistic target of Rapamycin
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(mTOR1) complex (mTORC1) via stimulation of GTPase
activity of the small GTPase Rheb [5]. Although the
majority of LAM tissues characteristically carry TSC1 or
TSC2 mutations, a signiﬁcant number of cases (10–15%)
still present with no mutations in the TSC genes, suggesting
undetected mutagenic events or deregulation of signaling
pathways via an alternative route [6] which possibilities are
actively researched in leading laboratories of the ﬁeld [7].
Currently, treatment options remain limited to the mTOR
inhibitor Rapamycin (Sirolimus) [8] that stabilizes lung
function in most patients but does not offer progression-free
survival.
As LAM occurs almost exclusively in women, some
clinical studies have claimed that control of serum estrogen
levels offers up an alternative route to preventing disease
progression [9]. Although such attempts have mostly failed
[9], we theorized that it was not the original idea but the
study approach that might have been unsuccessful. In an
attempt to understand more fully the broader disease
mechanisms (in addition to TSC mutations) that might
mediate LAM pathogenesis, we have performed TaqMan
and Nanostring array analysis of LAM cells isolated directly
from the lungs of transplant patients [10]. Through a
combination of techniques, we have identiﬁed gene
expression proﬁles and miRNA signatures that strongly
indicate that an alteration in mitochondrial biogenesis and
function are among the key determinants behind increased
VEGF production and accelerated cell proliferation. To test
our conclusions, we have also treated LAM cell lines with
the potent, mito-targeting and mito-active drug candidate
Proxison [11] and observed restoration of mitochondrial
function and a corresponding reduction in VEGF produc-
tion and proliferation capacity.
Results
Deregulation of nuclear receptors, vascularization,
and miRNAs in LAM
Estrogen hormone affects cellular signaling and metabo-
lism via two receptor types located on the cell membrane
(Estrogen Receptor A or ERA) and within the nucleus
(Estrogen Receptor B or ERB) [12]. A nuclear receptor
array was performed using pooled samples of two indi-
vidual bronchial smooth muscle cell (SMC) controls and
pooled samples from four LAM patient-derived cell lines
(Fig. 1a) (Supplementary Table 1 and Fig. 1). Of the 92
examined genes, 21 have shown an increase, and a further
30 a reduction in expression levels when compared to
normal SMCs. The nuclear receptor TaqMan array
(Fig.1b) and consequent quantitative reverse transcription
polymerase chain reaction (qRT-PCR) analysis on indi-
vidual cell types (Supplementary Fig. 2) identiﬁed
the progesterone receptor (PGR), the peroxisome
proliferator-activated receptor gamma coactivator 1-beta
(PPARGC1B) as being signiﬁcantly overexpressed, and
estrogen-related receptor gamma (ESRRG) as markedly
upregulated. PPARGC1B is known to regulate the tran-
scriptional activity of the estrogen receptor alpha (ERA),
nuclear respiratory factor 1 (NRF1), and glucocorticoid
receptor (GR) genes. The expression of each of these
genes increased over seven-fold in the LAM cell lines
tested (Fig. 1b). PPARGC1B overexpression is linked to
increased mitochondrial number [13, 14], the active PRG
isoform 4 to increased mitochondrial membrane potential
and cellular respiration [13, 14], while ESRRG to control
of mitochondrial biogenesis and energy metabolism [6,
14]. The signiﬁcantly down-regulated nuclear receptor
genes included NR5A2 and retinoic acid receptor beta
(RARB). RARB is a member of thyroid-steroid hormone
receptor superfamily (Fig. 1b) and both genes are known
to play a powerful role in the inhibition of proliferation
and stimulation of cellular differentiation [15]. Artiﬁcial
Neural Network (ANN) analysis [16] of the data sets
revealed a strong positive correlation with several retinoic
acid receptors (RARB, RXRB, and RXRG) all of which
bind the biologically active form of vitamin A and PGR
(Fig. 1b). Changes in nuclear receptor gene expression in
the disease cell lines directly point towards strong mito-
chondrial involvement in LAM linking data to previous
studies demonstrating that LAM cell proliferation, driven
by mTOR activation, requires major adjustments in
energy metabolism [17]. Instead of utilizing NADP-
driven oxidative phosphorylation, mitochondrial energy
production by LAM sufferers (also seen in some cancers)
is predominantly limited to aerobic glycolysis (Warburg
effect) [17]. Such changes in energy metabolism lead to
an increased expression of the hypoxia-inducible factor 1
alpha (HIF1-alpha) [17, 18] (Fig. 1c), and consequently to
increase in VEGF expression [19]. In support, qRT-PCR
analysis (Fig. 1c) and an angiogenesis protein array
(Fig. 1c) detected strong up-regulation of LAM diagnostic
markers VEGFC and VEGFD (Fig. 1c). A decrease in
thrombospondin-1 (TSP1) and an increase in CXCL16
chemokine peptide levels were also observed in the LAM
samples (Fig. 1d). These observations are particularly
interesting as TSP1 is a recognized inhibitor of mito-
chondrial biogenesis [20], while CXCL16 regulates cel-
lular invasion in non-small-cell lung cancer (NSCLC)
[21]. ANN analysis of the angiogenesis array data (Fig.
1e) identiﬁed a strong association of CXCL16 and TSP1
with the ﬁbroblast growth factor (FGF), Endothelin1,
SerpinE1, and VEGFC (Fig. 1e) levels that are all
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involved in the stimulation of vascularization and
the induction of myoﬁbroblastic phenotype that in
itself can reduce the capacity for pulmonary regeneration
[22].
Further studies using a Nanostring methodology identi-
ﬁed down-regulation of both the tumor suppressor
miR125b-5p [23] and the low-density lipid oxidation
induced autophagy regulator miR155-5p [24] in LAM. The
apoptosis inducer miR-15b-5p [24] was down-regulated,
while the cell proliferation and survival inducer miR-199a/
b-3p [24] had increased copy numbers in individual LAM
samples (Fig. 1f).
Based on the data above, compromised mitochondrial
activity is appeared to be an additional factor in LAM
disease progression.
Mitochondrial dysfunction in LAM
Electron microscopic images of the normal SMC and LAM
cell lines showed a drastically different mitochondrial
Fig. 1 Morphological and molecular characterization of bronchial
SMC controls and LAM cell lines. a Study rationale and cellular
morphology. Normal bronchial SMC controls (n= 2) and patient-
derived LAM cell lines (n= 4) were stained for hematoxylin eosin
(magniﬁcation ×10, size-bar 200 μm) and for alpha-smooth muscle
actin (ASMA) (ASMA green, DAPI blue, magniﬁcation ×40, size bar
40 μm). Electron microscopy of mitochondria in LAM cells and nor-
mal bronchial SMC controls (magniﬁcation 200 nm, the scale bar 500
nm). b Nuclear receptor TaqMan arrays n= 2 (data were generated
from pooled samples of normal bronchial SMC controls n= 2, or
patient derived LAM cell lines n= 4, respectively). Heat map of
LogRQ values are shown. Nuclear receptor TaqMan data presented as
LogRQ ± technical error of the replicates. ANN analysis of the nuclear
receptor arrays was performed to demonstrate hidden interactions
among different nuclear receptors. c Deregulation of VEGF expression
in LAM samples. qRT-PCR analysis of genes affecting angiogenesis
were performed and beta-actin was used as inner control. Data are
presented as mean of log RQ ± SEM. Signiﬁcant changes are marked
as asterisk (P < 0.05); d Heat map of angiogenesis protein array. The
ﬁgure presents mean of pixel intensity. e Angiogenesis array results of
LAM cell lines n= 3 and normal SMC control n= 2 presented as
mean of pixel intensity ± SEM. Signiﬁcant changes are marked as
asterisk (P < 0.05). ANN analysis of angiogenesis protein interaction
hierarchy. f Analysis of 798 miRNA absolute copy numbers by
Nanostring. miRNA copy numbers detected by Nanostring in pooled
LAM (n= 4) and pooled, normal SMC (n= 2) samples. The heat map
represents the most deregulated 141 miRNA in LAM samples com-
pared to normal SMC controls. Copy number differences of speciﬁc
miRNAs that are involved in mitochondrial biogenesis detected after
Nsolver analysis were further analyzed in individual cell lines (normal
SMCs (n= 2) and LAM (n= 4)). Data are presented as average copy
number ± SEM, signiﬁcant changes are marked as asterisk (P < 0.05)
Mitochondrial dysfunction is a key determinant of the rare disease lymphangioleiomyomatosis and. . . 3095
morphology (Fig. 1a) (Supplementary Fig. 3). Mitochondria
in LAM cells were smaller, darker, and so electro-dense that
the inner membrane cristae were not visible (Fig. 1a). The
gene proﬁling data again support these microscopic obser-
vations. NRF1 encodes a homodimerizing protein, which
functions as a transcription factor for key metabolic genes
required for cellular growth, respiration, mitochondrial
DNA transcription, and replication. NRF1 was higher in
LAM than in control SMCs (Fig. 2a) and has previously
[25] been linked to PPARGC1B gene expression (Fig. 1b).
PPARGC1B in turn is responsible for constitutive non-
adrenergic-mediated mitochondrial biogenesis via increased
basal oxygen consumption [25], fat oxidation, non-
oxidative glucose metabolism, and regulation of energy
expenditure [25]. A pathway of biochemical events that
seems to be conﬁrmed here by the increase seen in HIF1
levels (Fig. 1c) and the corresponding overexpression of the
VEGF gene family (Fig. 1c).
Additional markers of “mitochondrial health” showed
signiﬁcant changes. The mitochondrial transcription factor
A (TFAM) that encodes a protein critical in both mito-
chondrial DNA repair and replication was higher in
diseased LAM cell lines than in normal SMC controls
(Fig. 2a). The observed alterations in transcription levels
appeared to impact on all aspects of mitochondrial function.
Both CytoC (cytochrome complex), an inner membrane
protein of the mitochondria that is an essential component
of the electron transport chain [26], as well as Cox4
(cytochrome c oxidase) that catalyzes oxygen reduction [26]
were signiﬁcantly elevated (Fig. 2a).
To investigate overall mitochondrial activity, a combi-
nation of ﬂow cytometric analysis of the mitochondrial
Fig. 2 Altered function of mitochondria in LAM cells. a qRT-PCR
analysis of mitochondrial gene expression in individual LAM cell lines
(n= 4) compared to normal SMC controls (n= 2). Data are presented
as mean log RQ ± SEM and signiﬁcant changes are marked as asterisk
(P < 0.05). b Flow cytometric analysis of RH-123 ﬂuorescence
intensity in individual LAM cell lines (n= 4) compared to normal
SMC controls (n= 2). Data are presented as mean RFU ± SEM; sig-
niﬁcant changes are marked as asterisk (P < 0.05). c Oxygen con-
sumption rate and glycolysis were measured by SeaHorse XF96
in individual LAM (n= 4) cell lines and normal SMC control cells
(n= 2). Representative OCR and ECAR data are presented as mean ±
SEM, signiﬁcant changes are marked as asterisk (* P < 0.05). d
Measurements of mitochondrial activity. Oxygen consumption rate of
mitochondria measured using Oroboros (blue line= oxygen con-
centration, red line= oxygen ﬂux per volume; quantiﬁcation of oxy-
gen consumption (area under the curve). e TrxR activity measured in
individual LAM (n= 4) and normal, bronchial SMC control (n= 2)
samples. Data are TrxR; activity is presented as mean of nmol min/ml
± SEM; signiﬁcant changes are marked as asterisk (P < 0.05)
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membrane Rhodamine-123 (RH-123) a cell-permeable,
cationic, green-ﬂuorescent dye, Oroboros, and Seahorse
analyses were performed. Mitochondrial energization
induces quenching of RH-123 ﬂuorescence and the rate of
ﬂuorescence decay is proportional to mitochondrial mem-
brane potential. Based on this analysis, LAM mitochondrial
membrane activity is twice as high as that seen in normal,
SMC controls (Fig. 2b). In contrast, increased glycolysis
and reduced oxidation was detected by metabolic analysis
of LAM cells using Seahorse (Fig. 2c) and Oroboros
technology (Fig. 2d). At ﬁrst sight, these biochemical
results may appear contradictory, however, during reductive
stress, when electron acceptors are expected to be mostly
reduced, some redox proteins can donate electrons to O2
instead. This process can increase net mitochondrial reac-
tive oxygen species (ROS) production, despite the con-
comitant enhancement of ROS scavenging systems [27].
For example, normally antioxidant matrix NADPH reduc-
tases, together with glutathione reductases and thioredoxin
reductases (TrxR) [28], can all go on to generate H2O2 by
leaking electrons from their reduced ﬂavoprotein to O2.
Generation of this net mitochondrial ROS spill-over can
cause oxidative injury and can critically damage mito-
chondria. The process by which cells remove these
damaged or dysfunctional mitochondria is known as mito-
phagy. Any damage to the mitophagy process may result in
abnormal mitochondrial function. To test this theory, TrxR
activity was determined in both normal, SMCs, and LAM
cell lines. In the latter, TrxR activity was signiﬁcantly
higher than in normal SMC controls (Fig. 2e).
Interestingly, the Trx2–TrxR2 system has been reported
to be an anti-angiogenic target of auranoﬁn, a redox enzyme
inhibitor gold complex [28]. The high afﬁnity of auranoﬁn
for thiol and selenol groups and through the inhibition of
redox enzymes such as TrxR can modify the redox balance
in mitochondria [28]. Our studies reported here, together
with the above supporting evidence from the published
literature, we theorized that drugs that can inhibit TrxR
activity and restore normal mitochondrial function might be
able to reduce LAM progression.
Mitochondria as a potential therapeutic target in
LAM
The novel synthetic ﬂavonoid, Proxison (7-decyl-3-
hydroxy-2-(3,4,5-trihydroxyphenyl)-4-chromenone)
(Antoxis Ltd, UK), is a potent antioxidant accessing the
mitochondria [11]. Proxison combines key structural attri-
butes of the natural ﬂavonoid myricetin [29], with a stra-
tegically placed lipophilic chain to effectively protect cell
membranes from lipid peroxidation [11, 29]. To test the
effects of Proxison, both normal SMCs and LAM cell lines
were treated with the drug (Supplementary Fig. 4).
Mitochondrial activity was measured using RH-123 (Fig.
3a, b) and TrxR activity (Fig. 3e). Both tests showed
striking normalization of mitochondrial function in LAM
cell lines while Proxison appeared to have had little or no
effect on normal SMCs. Rapid improvement was detected
in the mitochondrial morphology of LAM cells with cristae
of the inner membrane becoming visible again by electron
microscopy (Fig. 3c). Morphological changes were asso-
ciated with the reduced gene expression of CytoC, NRF1,
TFAM, and Cox4 (Fig. 3d) as well as with gene expression
of VEGF ligands and receptors falling back to normal levels
(Fig. 3f). Additional functional studies, scratch and migra-
tion assays have shown that Proxison treatment reduced the
proliferation (Fig. 3g) and migration capacity (Fig. 3h) of
LAM cells and such effect was additive to Rapamycin
treatment in both gene expression and cellular migration
(Supplementary Figs 5 and 6).
Discussion
While earlier publications may have hinted at the impor-
tance of energy metabolism in the pathogenesis of LAM [6],
this is the ﬁrst detailed molecular analysis of patient-derived
LAM cell lines, allowing the assessment of mitochondrial
function and biogenesis to be deﬁned in the pathomechan-
ism of LAM, and its utility as a novel target for therapy
investigated.
Mitochondrial biogenesis is under multifactorial regula-
tion with hormones such as estrogen [30] known to have a
profound effect on activity. This complex biochemistry is
coordinated through a network of transcriptional coactiva-
tors such as PPARGC1A and PPARGC1B [31] together
with PPARs (peroxisome proliferator-activating receptors),
ERRs (estrogen-related receptors), and NRF1 hormones and
in concert they are able to inﬂuence and control aspects of
energy metabolism [32]. Gene proﬁling has conﬁrmed that
the expression of all these nuclear receptors and/or coacti-
vators are upregulated in LAM pathology. Taken together
these data strongly support the conclusion that mitochondrial
malfunction has a key role in LAM disease. Experiments
with the mitochondria targeting Proxison, a novel pre-
clinical drug candidate [11, 29, 33] appeared to sufﬁciently
“heal” the critically damaged mitochondria in LAM. In
migration assays the inhibitory effects of Proxison
were additive to Rapamycin which result needs further
evaluation.
In summary, we believe our study added a novel angle to
the current understanding of the condition LAM and have
proposed through Fig. 4 how the original importance of
mTORC1 [6], and its links to disease progression, ﬁts
alongside the new hypothesis that mitochondrial metabo-
lism is an additional therapeutic target.
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Materials and methods
Lung tissue samples were obtained from human lung
transplant donors, in accordance with the Declaration of
Helsinki and approved by the Institutional Review Board at
the University of Pennsylvania [5]. Four patient derived cell
lines LAM-100, LAM-111C, LAM-D9065, and LAM-HUP
were used in the present study. Controls were primary,
Fig. 3 Proxison normalizes mitochondrial morphology and function in
LAM cells. a Proxison (3 µM, 1 h)-treated normal SMC and LAM
cells were incubated with 2.5 µM RH-123 and then ﬂuorescence
microscopy was used to analyze ﬂuorescence intensity (magniﬁcation
×20, scale bar 50 µm). Quantiﬁcation of ﬂuorescence intensity in living
cells was performed using ImageJ software. Data are presented as pixel
intensity ± SEM; signiﬁcant changes are marked as asterisk (P < 0.05).
b Proxison (3 µM, 1 h)-treated normal SMC and LAM cells were
incubated with 2.5 µM RH-123 and then ﬂuorescence was analyzed by
ﬂow cytometry. Data are presented as mean of RFU ± SEM; signiﬁcant
changes marked as * P < 0.05. c Representative morphological chan-
ges in the mitochondria of LAM cell lines following Proxison treat-
ment. Electron microscopy of mitochondria of untreated and Proxison
(3 µM, 1 h)-treated LAM cells and normal SMC control cells (scale
bars are 500 and 200 nm, respectively). d qRT-PCR analysis of
mitochondrial gene expression in untreated and Proxison (3 µM, 1 h)
treated LAM cell lines (n= 4) compared to normal SMC controls
(n= 2); Data are presented as mean log RQ ± SEM and signiﬁcant
changes are marked as asterisk, solid circle, solid rhombus, and solid
square (P < 0.05). e TrxR activity of Proxison (3 µM, 1h)-treated LAM
cell lines (n= 4) compared to normal SMC controls (n= 2). TrxR
activity is presented as mean ± SEM and signiﬁcant changes are
marked as asterisk (P < 0.05). f qRT-PCR analysis of angiogenesis
related gene expression in untreated and Proxison (3 µM, 1 h)-treated
cell cultures (LAM n= 4, normal bronchial SMC n= 2). Data are
presented as mean RQ ± SEM and signiﬁcant changes are marked as
asterisk, solid circle, and solid triangle (in all results signiﬁcance was
P < 0.05). g Proliferation capacity following Proxison treatment (n= 3
technical repeats). Representative pictures of scratch assays in
untreated and Proxison (3 µM, 1 h)-treated LAM cell lines (n= 4)
compared to normal SMC controls (n= 2) after 12 h incubation. Data
are presented as mean of cell growth (gap) area nm2 ± SEM; signiﬁcant
changes are marked as asterisk (P < 0.05). h Migration capacity of
LAM cell lines. LAM cell lines (n= 2) and normal SMCs (n= 2) were
treated with Rapamycin (20 nM, 24 h), Proxison (3 µM, 24 h), Rapa-
mycin (20 nM, 24 h)+Proxison(3 µM, 24 h), and ﬁnally cells were pre-
treated with Rapamycin for 48 h (20 nM/24 h) and then incubated with
Proxison (3 µM, 24 h). Images are presented as the number of cells
migrated through the membrane to the lower side of the chamber and
were stained with DAPI. Data are presented as the percentage of
migrated LAM cells compared to normal SMC ± SEM and signiﬁcant
changes are marked as (1), (2), (3), (4) and (5) (in all results sig-
niﬁcance was P < 0.05)
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normal human bronchial SMCs (Lonza, Basel, Switzer-
land). Electron microscopy on 90-nm-thick sections were
performed using a Jeol 1200 and Jeol 1400 transmission
electron microscope (Jeol Ltd, Tokyo, Japan) at 80 kV.
Images were acquired using an integrated MegaView III
digital camera (Olympus Soft Imaging Solutions GmbH,
Munster, Germany). Flow cytometry was performed on
Rhodamine-123 (RH-123) (Sigma-Aldrich, St Louis, MO,
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USA)-treated cell suspensions using a FACS Canto II ﬂow
cytometer (BD Immunocytometry Systems, Erembodegen,
Belgium). Fluorescence microscopy images were acquired
by an Olympus IX-81 (OLYMPUS Corporation, Tokyo,
Japan) light and ﬂuorescent microscope. RNA was isolated
with MN NucleoSpin RNA isolation kit (Macherey-Nagel,
Düren, Germany). RNA concentration was measured using
NanoDrop (Thermo Fisher Scientiﬁc, Waltham, USA).
Human Nuclear Receptors TaqMan®Array (Thermo Fisher
Scientiﬁc, Waltham, USA). TaqMan PCR reaction was
performed using ABI StepOnePlus system and data were
analyzed with StepOne software. MicroRNA expression
was normalized to U6 expression. Nanostring assay was
analyzed using the nCounter Analysis System (NanoString
Technologies, Washington, USA). Angiogenesis was
assessed using a Human Angiogenesis Array Kit (R&D
Systems, Minneapolis, USA). Protein concentration was
determined using a ﬂuorescent protein assay (Qubit protein;
Thermo Fisher Scientiﬁc, Waltham, USA). Quantitative
RT-PCR was performed using SensiFAST SYBR Green
reagent (BioLine, London, UK) in an ABI StepOnePlus
system (Thermo Fisher Scientiﬁc, Waltham, USA) and data
were analyzed with StepOne software and normalized to
beta-actin as a housekeeping gene and calculated according
to the 2−ddCt method. Array data were evaluated using a
feedforward artiﬁcial neural network (ANN) (Neurosolu-
tions 6; NeuroDimension Inc.) software. Metabolic proﬁling
was performed using SeaHorse XF96 (Agilent Technolo-
gies, USA) [11] and Oroboros (O2k, OROBOROS Instru-
ments, Innsbruck, Austria) platforms [12]. Transwells were
used for migration assay (Costar, Corning Incorporated,
Sigma-Aldrich, St Louis, MO, USA). TRXR activity was
assessed using a Thioredoxin Reductase Assay Kit (Abcam,
Cambridge, MA, USA). Statistical analysis was performed
using the independent samples t-test and one-way ANOVA
with Bonferroni correction. P < 0.05 was considered as
signiﬁcant. For extensively detailed Materials and methods
refer to Full Methods (Supplementary Material).
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